UCLA
No infographics yet
A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis
byUCLA
The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
byUCLA
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer
byUCLA
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer
byUCLA
No likes yet
Personal Information
Organization / Workplace
UCLALocation
San Francisco Bay Area, California United StatesOccupation
Professor at David Geffen School of Medicine at UCLAIndustry
Education
Website
www.MiraKind.orgAbout
I am an oncologist and molecular biologist, who has dedicated my life to improving the care of cancer patients. I have worked to apply novel and progressive scientific findings to critical issues in cancer care. Through these efforts I have started a genetics company, MiraDx, and a non-profit, MiraKind.